Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Antimicrobial Resistance & Infection Control
Published in: Antimicrobial Resistance & Infection Control 1/2019

Open Access 01-12-2019 | Photodynamic Therapy | Review

Antibiotics versus biofilm: an emerging battleground in microbial communities

Authors: Divakar Sharma, Lama Misba, Asad U. Khan

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2019

Login to get access

Abstract

Biofilm is a complex structure of microbiome having different bacterial colonies or single type of cells in a group; adhere to the surface. These cells are embedded in extracellular polymeric substances, a matrix which is generally composed of eDNA, proteins and polysaccharides, showed high resistance to antibiotics. It is one of the major causes of infection persistence especially in nosocomial settings through indwelling devices. Quorum sensing plays an important role in regulating the biofilm formation. There are many approaches being used to control infections by suppressing its formation but CRISPR-CAS (gene editing technique) and photo dynamic therapy (PDT) are proposed to be used as therapeutic approaches to subside bacterial biofim infections, especially caused by deadly drug resistant bad bugs.
Literature
1.
Abranches J, Miller JH, Martinez AR, Simpson-Haidaris PJ, Burne RA, Lemos JA. The collagen-binding protein Cnm is required for Streptococcus mutans adherence to and intracellular invasion of human coronary artery endothelial cells. Infect Immun. 2011;79:2277–84.CrossRefPubMedPubMedCentral
2.
Alekshun MN, Levy SB. The mar regulon: multiple resistances to antibiotics and other toxic chemicals. Trends Microbiol. 1999;7:410–3.CrossRefPubMed
3.
Almas K, Al-Bagieh NH. The antimicrobial effects of bark and pulp extracts of miswak, Salvadora persica. Biomed letters. 1999;60:71–5.
4.
5.
Anderl JN, Franklin MJ, Stewart PS. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother. 2000;44:1818–24.CrossRefPubMedPubMedCentral
6.
Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW. Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials. Biomaterials. 2012;33:5967–82.CrossRefPubMed
7.
Arias ME, Gorney JD, Cadmani NM, Vattuone MA, Isla MI. Antibacterial activity of ethonolic and aqueous extracts of Acacia aroma. Ex Hook et. Arn. Life Sci. 2004;75:191–202.CrossRefPubMed
8.
Ayrapetyan M, Williams TC, Oliver JD. Bridging the gap between viable but non-culturable and antibiotic persistent bacteria. Trends Microbiol. 2015;23:7–13.CrossRefPubMed
9.
Baek YW, An YJ. Microbial toxicity of metal oxide nanoparticles (CuO, NiO, ZnO, and Sb2O3) to Escherichia coli, Bacillus subtilis, and Streptococcus aureus. Sci Total Environ. 2011;409(8):1603–8.CrossRefPubMed
10.
Bagge N, Ciofu O, Skovgaard LT, Høiby N. Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase. APMIS. 2000;108:589–600.CrossRefPubMed
11.
Bakkiyaraj D, Pandian SK. In vitro and in vivo antibiofilm activity of a coral associated actinomycete against drug resistant Staphylococcus aureus biofilms. Biofouling. 2010;26:711–7.CrossRefPubMed
12.
Barraud N, Schleheck D, Klebensberger J, Webb JS, Hassett DJ, Rice SA, Kjelleberg S. Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J Bacteriol. 2009;191:7333–42.CrossRefPubMedPubMedCentral
13.
Basaraba RJ, Ojha AK. Mycobacterial biofilms: revisiting tuberculosis bacilli in extracellular necrotizing lesions. Microbiol Spectr. 2017;5(3).
14.
Beauclerk AAD, Cundliffe E. Site of action of two ribosomal RNA methylases responsible for resistance to aminoglycoside. J Mol Biol. 1987;193:661–71.CrossRefPubMed
15.
Beloin C, Ghigo JM. Finding gene-expression patterns in bacterial biofilms. Trends Microbiol. 2005;13:16–9.CrossRefPubMed
16.
Berbari EF, Hanssen AD, Duffy MC, Steckelberg JM, Osmon DR. Prosthetic joint infection due to Mycobacterium tuberculosis: a case series and review of the literature. Am J Orthop. 1998;27:219–27.PubMed
17.
Billings N, Birjiniuk A, Samad TS, Doyle PS, Ribbeck K. Material properties of biofilms- a review of methods for understanding permeability and mechanics. Rep Prog Phys. 2015;78:036601.CrossRefPubMedPubMedCentral
18.
Bjarnsholt T, Jensen PO, Rasmussen TB, Christophersen L, Calum H, Hentzer M, Hougen HP, Rygaard J, Moser C, Eberl L, Høiby N. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology. 2005;15:3873–80.CrossRef
19.
Brooun A, Liu S, Lewis K. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2000;44:640–6.CrossRefPubMedPubMedCentral
20.
Brown MR, Allison DG, Gilbert P. Resistance of bacterial biofilms: a growth-related effect? J Antimicrob Chemother. 1988;22:777–83.CrossRefPubMed
21.
Burmolle M, Thomsen TR, Fazli M, Dige I, Christensen L, Homøe P, Tvede M, Nyvad B, Tolker-Nielsen T, Givskov M, Moser C. Biofilms in chronic infections – a matter of opportunity – monospecies biofilms in multispecies infections. FEMS Immunol Med Microbiol. 2010;59:324–36.CrossRefPubMed
22.
Caceres N, Vilaplana C, Prats C, Marzo E, Llopis I, Valls J, et al. Evolution and role of corded cell aggregation in Mycobacterium tuberculosis cultures. Tuberculosis. 2013;93:690–8.CrossRefPubMed
23.
Carpenter BL, Situ X, Scholle F, Bartelmess J, Weare WW, Ghiladi RA. Antiviral, antifungal and antibacterial activities of a BODIPY-based photosensitizer. Molecules. 2015;20:10604–21.CrossRefPubMedPubMedCentral
24.
Chung PY. The emerging problems of Klebsiella pneumoniae infections: carbapenem resistance and biofilm formation. FEMS Microbiol Lett. 2016;363:219.CrossRef
25.
Cochran WL, McFeters GA, Stewart PS. Reduced susceptibility of thin Pseudomonas aeruginosa biofilms to hydrogen peroxide and monochloramine. J Appl Microbiol. 2000;88:22–30.CrossRefPubMed
26.
Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. Int J Artif Org. 2005;28:1062–8.CrossRef
27.
Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–22.CrossRefPubMed
28.
29.
Das JR, Bhakoo M, Jones MV, Gilbert P. Changes in the biocide susceptibility of Staphylococcus epidermidis and Escherichia coli cells associated with rapid attachment to plastic surfaces. J Appl Microbiol. 1998;84:852–8.CrossRefPubMed
30.
Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 2003;2(2):114–22.CrossRefPubMed
31.
Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science. 1998;280:295–8.CrossRefPubMed
32.
de Beer D, Stoodley P, Roe F, Lewandowski Z. Effects of biofilm structure on oxygen distribution and mass transport. Biotechnol Bioeng. 1994;43:1131–8.CrossRefPubMed
33.
de la Fuente-Nú˜nez C, Reffuveille F, Fernandez L, REW H. Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Curr Opi Microbiol. 2013;16:580e589.
34.
35.
Esteban J, Martín-de-Hijas NS, Kinnari TJ, Ayala G, Fernández-Roblas R, Gadea I. Biofilm development by potentially pathogenic non-pigmented rapidly growing mycobacteria. BMC Microbiol. 2008;8:184.CrossRefPubMedPubMedCentral
36.
Esteban J, Martín-de-Hijas NZ, García-Almeida D, Bodas-Sánchez A, Gadea I, Fernandez-Roblas R. Prevalence of erm methylase genes in clinical isolates of non-pigmented, rapidly growing mycobacteria. Clin Microbiol Infect. 2009;15:919–23.CrossRefPubMed
37.
Falkinham JO III. Nontuberculous mycobacteria in the environment. Clin Chest Med. 2002;23:529–51.CrossRefPubMed
38.
Falkinham JOIII. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol. 2009;107:356–67.CrossRefPubMed
39.
40.
Flemming HC, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol. 2016;14(9):563–75.CrossRefPubMed
41.
Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol. 2005;13:34–40.CrossRefPubMed
42.
Gordon CA, Hodges NA, Marriott C. Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosisderived Pseudomonas aeruginosa. J Antimicrob Chemother. 1988;22:667–74.CrossRefPubMed
43.
Goto T, Nakame Y, Nishida M, Ohi Y. In vitro bactericidal activities of beta-lactamases, amikacin, and fluoroquinolones against Pseudomonas aeruginosa biofilm in artificial urine. Urology. 1999;53:1058–62.CrossRefPubMed
44.
Greendyke R, Byrd TF. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. Antimicrob Agents Chemother. 2008;52:2019–26.CrossRefPubMedPubMedCentral
45.
Ha KY, Chung YG, Ryoo SJ. Adherence and biofilm formation of Staphylococcus epidermidis andMycobacteriumtuberculosis on various spinal implants. Spine. 2005;30:38–43.CrossRefPubMed
46.
Halloum I, Carrere-Kremer S, Blaise M, Viljoen A, Bernut A, Le Moigne V, et al. Deletion of a dehydratase important for intracellular growth and cording renders roughMycobacterium abscessus avirulent. Proc Natl Acad Sci U S A. 2016;113:E4228–37.CrossRefPubMedPubMedCentral
47.
Helaine S, Kugelberg E. Bacterial persisters: formation, eradication, and experimental systems. Trends Microbiol. 2014;22:417–24.CrossRefPubMed
48.
Hernández-Sierra JF, Ruiz F, Cruz Pena DC. The antimicrobial sensitivity of Streptococcus mutans to nanoparticles of silver, zinc oxide, and gold. Nanomedicine. 2008a;4:237–40.CrossRefPubMed
49.
Hernández-Sierra JF, Ruiz F, Pena DC, Martínez-Gutiérrez F, Martínez AE, Guillén Ade J, Tapia-Pérez H, Castañón GM. The antimicrobial sensitivity of Streptococcus mutans to nanoparticles of silver, zinc oxide, and gold. Nanomed. 2008b;4:237–40.CrossRef
50.
Hochbaum AI, Kolodkin-Gal I, Foulston L, Kolter R, Aizenberg J, Losick R. Inhibitory effects of D-amino acids on Staphylococcus aureus biofilm development. J Bacteriol. 2011;193:5616–22.CrossRefPubMedPubMedCentral
51.
Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK, Givskov M, Høiby N. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr2/2 mice. Antimicrob Agents Chemother. 2007;51:3677–87.CrossRefPubMedPubMedCentral
52.
Hoiby N, Ciofu O, Johansen HK, Song ZJ, Moser C, Jensen PØ, Molin S, Givskov M, Tolker-Nielsen T, Bjarnsholt T. The clinical impact of bacterial biofilms. Int J Oral Sci. 2011;3:55.CrossRefPubMedPubMedCentral
53.
Huse HK, Kwon T, Zlosnik JE, Speert DP, Marcotte EM, Whiteley M. Pseudomonas aeruginosa enhances production of a non-alginate exopolysaccharide during long-term colonization of the cystic fibrosis lung. PLoS One. 2013;8:e82621.CrossRefPubMedPubMedCentral
54.
Iannitelli A, Grande R, Di Stefano A, Di Giulio M, Sozio P, Bessa LJ, Laserra S, Paolini C, Protasi F, Cellini L. Potential antibacterial activity of carvacrol-loaded poly (DL-lactide-co-glycolide) (PLGA) nanoparticles against microbial biofilm. Int J Mol Sci. 2011;12(8):5039–51.CrossRefPubMedPubMedCentral
55.
Islam MS, Richards JP, Ojha AK. Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms. Expert Rev Anti-Infect Ther. 2012;10:1055–66.CrossRefPubMedPubMedCentral
56.
Jackson DW, Suzuki K, Oakford L, Simecka JW, Hart ME, Romeo T. Biofilm formation and dispersal under the influence of the global regulator CsrA of Escherichia coli. J Bacteriol. 2002;184:290–301.CrossRefPubMedPubMedCentral
57.
Kalpana BJ, Aarthy S, Pandian SK. Antibiofilm activity of α-amylase from Bacillus subtilis S8-18 against biofilm forming human bacterial pathogens. Appl Biochem Biotechnol. 2012;167(6):1778–94.CrossRefPubMed
58.
Kaur G, Balamurugan P, Vasudevan S, Jadav S, Princy SA. Antimicrobial and Antibiofilm potential of acyclic amines and diamines against multi-drug resistant Staphylococcus aureus. Front Microbiol. 2017;8:1767.CrossRefPubMedPubMedCentral
59.
Kennedy BS, Bedard B, Younge M, Tuttle D, Ammerman E, Ricci J, et al. Outbreak of Mycobacterium chelonae infection associated with tattoo ink. N Engl J Med. 2012;367:1020–4.CrossRefPubMed
60.
61.
Khan W, et al. Aminoglycoside resistance of Pseudomonas aeruginosa biofilms modulated by extracellular polysaccharide. Int Microbiol. 2010;13:207–12.PubMedPubMedCentral
62.
Kohler P, Kuster SP, Bloemberg G, Schulthess B, Frank M, Tanner FC, et al. Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections subsequent to open heart surgery. Eur Heart J. 2015;36:2745–53.CrossRefPubMed
63.
Kolodkin-Gal I, Cao S, Chai L, Bo¨ttcher T, Kolter R, Clardy J, Losick R. A self-produced trigger for biofilm disassembly that targets exopolysaccharide. Cell. 2012;149:684–92.CrossRefPubMedPubMedCentral
64.
65.
Kragh KN, Hutchison JB, Melaugh G, Rodesney C, Roberts AEL, Irie Y, Jensen PØ, Diggle SP, Allen RJ, Gordon V, Bjarnsholt T. Role of multicellular aggregates in biofilm formation. mBio. 2016;7(2):e00237–16.CrossRefPubMedPubMedCentral
66.
67.
Kulka K, Hatfull G, Ojha AK. Growth of Mycobacterium tuberculosis biofilms. J Vis Exp. 2012;15:e3820.
68.
Kulshrestha S, Khan S, Hasan S, Khan ME, Misba L, Khan AU. Calcium fluoride nanoparticles induced suppression of Streptococcus mutans biofilm: an in vitro and in vivo approach. Appl Microbiol Biotechnol. 2016;100:1901–14.CrossRefPubMed
69.
Kulshrestha S, Khan S, Meena R, Khan AU. A graphene/zinc oxide nanocomposite film protects dental implant surfaces against cariogenic Streptococcus mutans. Biofouling. 2014;30:1281–94.CrossRefPubMed
70.
Kumar B, Sharma D, Sharma P, Katoch VM, Venkatesan K, Bisht D. Proteomic analysis of Mycobacterium tuberculosis isolates resistant to kanamycin and amikacin. J Proteome. 2013;94:68–77.CrossRef
71.
Kumon H, Tomochika K, Matunaga T, Ogawa M, Ohmori H. A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides. Microbiol Immunol. 1994;38:615–9.CrossRefPubMed
72.
Lata M, Sharma D, Deo N, Tiwari PK, Bisht D, Venkatesan K. Proteomic analysis of ofloxacin-mono resistant Mycobacterium tuberculosis isolates. J Proteome. 2015;127:114–21.CrossRef
73.
Li L, Mendis N, Trigui H, Oliver JD, Faucher SP. The importance of the viable-but nonculturable state in human bacterial pathogens. Front Microbiol. 2014;5:258.PubMedPubMedCentral
74.
Lonn-Stensrud J, Landin MA, Benneche T, Petersen FC, Scheie AA. Furanones, potential agents for preventing Staphylococcus epidermidis biofilm infections. J Antimicrob Chemother. 2009;63:309–16.CrossRefPubMed
75.
Madsen JS, Burmølle M, Hansen HL, Sørensen SJ. The interconnection between biofilms formation and horizontal gene transfer. FEMS Immunol Med Microbiol. 2012;65:183–95.CrossRefPubMed
76.
Magnet S, Courvalin P, Lambert T. Resistance modulation cell division type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii BM4454. Antimicrob Agents Chemother. 2001;45:3375–80.CrossRefPubMedPubMedCentral
77.
Magnet S, Smith TA, Zheng R, Nordmann P, Blanchard JS. Aminoglycosides resistance resulting from tight drug binding to an altered aminoglycosides acetyl transferase. Antomicrob Agents Chemother. 2003;47:1577–83.CrossRef
78.
Mah T-F, O’Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001;9:34–9.CrossRefPubMed
79.
80.
Maisonneuve E, Gerdes K. Molecular mechanisms underlying bacterial persisters. Cell. 2014;157:539–48.CrossRefPubMed
81.
Maya-Hoyos M, Leguizamón J, Mariño-Ramírez L, Soto CY. Sliding motility, biofilm formation, and glycopeptidolipid production in Mycobacterium colombiense strains. Biomed Res Int. 2015;2015:419549.CrossRefPubMedPubMedCentral
82.
McCarty SM, Cochrane CA, Clegg PD, Percival SL. The role of endogenous and exogenous enzymes in chronic wounds: a focus on the implications of aberrant levels of both host and bacterial proteases in wound healing. Wound Repair Regen. 2012;20:125–36.CrossRefPubMed
83.
Menozzi FD, Rouse JH, Alavi M, Laude-Sharp M, Muller J, Bischoff R, et al. Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med. 1996;184:993–1001.CrossRefPubMed
84.
Metwalli KH, Khan SA, Krom BP, Jabra-Rizk MA. Streptococcus mutans, Candida albicans, and the human mouth: a sticky situation. PLoS Pathog. 2013;9:e1003616.CrossRefPubMedPubMedCentral
85.
Minardi D, Cirioni O, Ghiselli R, Silvestri C, Mocchegiani F, Gabrielli E, d’Anzeo G, Conti A, Orlando F, Rimini M, Brescini L. Efficacy of tigecycline and rifampin alone and in combination against enterococcus faecalis biofilm infection in a rat model of ureteral stent. J Surg Res. 2012;176:1–6.CrossRefPubMed
86.
87.
Misba L, Kulshrestha S, Khan AU. Antibiofilm action of a toluidine blue O-silver nanoparticle conjugate on Streptococcus mutans: a mechanism of type I photodynamic therapy. Biofouling. 2016;32(3):313–28.CrossRefPubMed
88.
Misba L, Zaidi S, Khan AU. A comparison of antibacterial and antibiofilm efficacy of phenothiazinium dyes between gram positive and gram negative bacterial biofilm. Photodiagn Photodyn Ther. 2017;18:24–33.CrossRef
89.
Monzón M, Oteiza C, Leiva J, Lamata M, Amorena B. Biofilm testing of Staphylococcus epidermidis clinical isolates: low performance of vancomycin in relation to other antibiotics. Diagn Microbiol Infect Dis. 2002;44:319–24.CrossRefPubMed
90.
Muñoz-Egea MC, Esteban M, Esteban J. “Inhibition of Mycobacterium abscessus biofilms by Methylobacterium sp,” in 29th ECCMI (Amsterdam); 2016.
91.
Muñoz-Egea MC, García-Pedrazuela M, Mahillo I, Esteban J. Effect of ciprofloxacin in the ultrastructure and development of biofilms formed by rapidly growing mycobacteria. BMC Microbiol. 2015;15:18.CrossRefPubMedPubMedCentral
92.
Muñoz-Egea MC, Garcia-Pedrazuela M, Mahillo-Fernandez I, Esteban J. Effect of antibiotics and antibiofilm agents in the ultrastructure and development of biofilms developed by nonpigmented rapidly growing mycobacteria. Microb Drug Resist. 2016;22:1–6.CrossRefPubMed
93.
Muñoz-Egea MC, García-Pedrazuela M, Mahillo I, García MJ, Esteban J. Autofluorescence as a tool for structural analysis of biofilms formed by nonpigmented rapidly growing mycobacteria. Appl Environ Microbiol. 2013;79:1065–7.CrossRefPubMedPubMedCentral
94.
95.
Nichols WW, Dorrington SM, Slack MPE, Walmsley HL. Inhibition of tobramycin diffusion by binding to alginate. Antimicrob Agents Chemother. 1988;32:518–23.CrossRefPubMedPubMedCentral
96.
97.
Nithya C, Devi MG, Karutha Pandian S. A novel compound from the marine bacterium Bacillus pumilus S6-15 inhibits biofilm formation in gram-positive and gram-negative species. Biofouling. 2011;27:519–28.CrossRefPubMed
98.
O’Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol. 2000;54:49–79.CrossRefPubMed
99.
O’Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol. 1998;30:295–304.CrossRefPubMed
100.
Ojha AK, Baughn AD, Sambandan D, Hsu T, Trivelli X, Guerardel Y, et al. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol. 2008;69:164–74.CrossRefPubMedPubMedCentral
101.
102.
Ojha A, Anand M, Bhatt A, Kremer L, Jacobs WR Jr, Hatfull GF. GroEL1: a dedicated chaperone involved in mycolic acid biosynthesis during biofilm formation in mycobacteria. Cell. 2005;123:861–73.CrossRefPubMed
103.
Ortiz-Perez A, Martin-de-Hijas N, Alonso-Rodriguez N, Molina-Manso D, Fernandez-Roblas R, Esteban J. Importance of antibiotic penetration in the antimicrobial resistance of biofilm formed by non-pigmented rapidly growing mycobacteria against amikacin, ciprofloxacin and clarithromycin. Enferm Infecc Microbiol Clin. 2011;29:79–84.CrossRefPubMed
104.
Otto M. Staphylococcal infections: mechanisms of biofilm maturation and detachment as critical determinants of pathogenicity. Annu Rev Med. 2013;64:175–88.CrossRefPubMed
105.
Oubekka SD, Briandet R, Fontaine-Aupart MP, Steenkeste K. Correlative time-resolved fluorescence microscopy to assess antibiotic diffusion reaction in biofilms. Antimicrob Agents Chemother. 2012;56:3349–58.CrossRef
106.
Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev. 2013;65:1803–15.CrossRefPubMed
107.
Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T. Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci. 2009;24:259–68.CrossRefPubMed
108.
Prigent-Combaret C, Vidal O, Dorel C, Lejeune P. Abiotic surface sensing and biofilm-dependent regulation of gene expression in Escherichia coli. J Bacteriol. 1999;181:5993–6002.PubMedPubMedCentral
109.
Qu Y, Daley AJ, Istivan TS, Rouch DA, Deighton MA. Densely adherent growth mode, rather than extracellular polymer substance matrix build-up ability, contributes to high resistance of Staphylococcus epidermidis biofilms to antibiotics. J Antimicrob Chemother. 2010;65:1405–11.CrossRefPubMed
110.
Qvist T, Pressler T, Høiby N, Katzenstein TL. Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis. Respir Res. 2014;15:1.CrossRef
111.
Recht J, Kolter R. Glycopeptidolipid acetylation affects sliding motility and biofilm formation in Mycobacterium smegmatis. J Bacteriol. 2001;183:5718–24.CrossRefPubMedPubMedCentral
112.
113.
Romero Diaz R, Picciafuoco S, Paraje MG, Angel Villegas N, Arce Miranda E, Albesa I, Cremonezzi D, Commisso R, Paglini-Oliva P. Relevance of biofilms in pediatric tonsillar disease. Eur J Clin Microbiol Infect Dis. 2011;30(12):1503–9.CrossRef
114.
Savage VJ, Chopra I, O’Neill AJ. Staphylococcus aureus biofilms promote horizontal transfer of antibiotic resistance. Antimicrob Agents Chemother. 2013;57:1968–70.CrossRefPubMedPubMedCentral
115.
Schulze-Robbecke R. Immun Infekt. 1993). [Mycobacteria in the environment;21:126–31.PubMed
116.
Schulze-Röbbecke R, Janning B, Fischeder R. Occurrence of mycobacteria in biofilm samples. Tuber Lung Dis. 1992;73:141–4.CrossRefPubMed
117.
Sharma D, Kumar B, Lata M, Joshi B, Venkatesan K, Shukla S, et al. Comparative proteomic analysis of aminoglycosides resistant and susceptible Mycobacterium tuberculosis clinical isolates for exploring potential drug targets. PLoS One. 2015;10(10):e0139414.CrossRefPubMedPubMedCentral
118.
Sharma D, Lata M, Singh R, Deo N, Venkatesan K, Bisht D. Cytosolic proteome profiling of aminoglycosides resistant Mycobacterium tuberculosis clinical isolates using MALDI-TOF/MS. Front Microbiol. 2016;7:1816.PubMedPubMedCentral
119.
Shigeta M, Tanaka G, Komatsuzawa H, Sugai M, Suginaka H, Usui T. Permeation of antimicrobial agents through Pseudomonas aeruginosa biofilms: a simple method. Chemotherapy. 1997;43:340–5.CrossRefPubMed
120.
Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000;407(6805):762–4.CrossRefPubMed
121.
Solano C, Echeverz M, Lasa I. Biofilm dispersion and quorum sensing. Curr Opin Microbiol. 2014;18:96–104.CrossRefPubMed
122.
Song Z, Kong KF, Wu H, Maricic N, Ramalingam B, Priestap H, Schneper L, Quirke JME, Høiby N, Mathee K. Panax ginseng has anti-infective activity against opportunistic pathogen Pseudomonas aeruginosa by inhibiting quorum sensing, a bacterial communication process critical for establishing infection. Phytomedicine. 2010;17:1040–6.CrossRefPubMedPubMedCentral
123.
Spinner RJ, Sexton DJ, Goldner RD, Levin LS. Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. J Arthroplast. 1996;11:217–22.CrossRef
124.
Stewart PS. A review of experimental measurements of effective diffusive permeabilities and effective diffusion coefficients in biofilms. Biotechnol Bioeng. 1998;59:261–72.CrossRefPubMed
125.
126.
Stewart PS, William Costerton J. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358:135–8.CrossRefPubMed
127.
Sugimoto S, et al. Imaging of bacterial multicellular behaviour in biofilms in liquid by atmospheric scanning electron microscopy. Sci Rep. 2016;6:25889.CrossRefPubMedPubMedCentral
128.
Sun F, Qu F, Ling Y, Mao P, Xia P, Chen H, Zhou D. Biofilm-associated infections: antibiotic resistance and novel therapeutic strategies. Future Microbiol. 2013;8:877–86.CrossRefPubMed
129.
Tack KJ, Sabath LD. Increased minimum inhibitory concentrations with anaerobiasis for tobramycin, gentamicin, and amikacin, compared to latamoxef, piperacillin, chloramphenicol, and clindamycin. Chemotherapy. 1985;31:204–10.CrossRefPubMed
130.
Takei S, Hotomi M, Yamanaka N. Minimal biofilm eradication concentration of antimicrobial agents against nontypeable Haemophilus influenzae isolated from middle ear fluids of intractable acute otitis media. J Infect Chemother. 2013;19:504–9.CrossRefPubMed
131.
Tetz GV, Artemenko NK, Tetz VV. Effect of DNase and antibiotics on biofilm characteristics. Antimicrob Agents Chemother. 2009;53:1204–9.CrossRefPubMed
132.
Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A. The rate of killing of Escherichia coli by β-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol. 1986;132:1297–304.PubMed
133.
van Ingen J, Boeree MJ, Dekhuijzen PN, van Soolingen D. Environmental sources of rapid growing nontuberculous mycobacteria causing disease in humans. Clin Microbiol Infect. 2009;15:888–93.CrossRefPubMed
134.
van Meervenne E, et al. Biofilm models for the food industry: hot spots for plasmid transfer? Pathog Dis. 2014;70:332–8.CrossRefPubMed
135.
Vijayaraghavan R, Chandrashekhar R, Sujatha Y, Belagavi CS. Hospital outbreak of atypical mycobacterial infection of port sites after laparoscopic surgery. J Hosp Infect. 2006;64:344–7.CrossRefPubMed
136.
Walker J, Moore G, Collins S, Parks S, Garvey MI, Lamagni T, et al. Microbiological problems and biofilms associated with Mycobacterium chimaera in heater-cooler units used for cardiopulmonary bypass. J. Hosp. Infect. 2017;96:209–20.CrossRefPubMed
137.
Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000;406:775–81.CrossRefPubMed
138.
Welch KT, Virga KG, Whittemore NA, Ozen C, Wright E, Brown CL, et al. Discovery of non-carbohydrate inhibitors of aminoglycoside-modifying enzymes. Bioorg Med Chem. 2005;13:6252–363.CrossRefPubMed
139.
Werner E, Roe F, Bugnicourt A, Franklin MJ, Heydorn A, Molin S, et al. Stratified growth in Pseudomonas aeruginosa biofilms. Appl Environ Microbiol. 2004;70:6188–96.CrossRefPubMedPubMedCentral
140.
Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science. 2002;295:1487.CrossRefPubMed
141.
Whiteley M, Bangera MG, Bumgarner RE, Parsek MR, Teitzel GM, Lory S, Greenberg EP. Gene expression in Pseudomonas aeruginosa biofilms. Nature. 2001;413:860–4.CrossRefPubMed
142.
Wiley L, Bridge DR, Wiley LA, Odom JV, Elliott T, Olson JC. Bacterial biofilm diversity in contact lens-related disease: emerging role of Achromobacter, Stenotrophomonas, and Delftia biofilm diversity in contact lens-related disease. Invest Ophthalmol Vis Sci. 2012;53:3896–905.CrossRefPubMed
143.
Wilkins M, Hall-Stoodley L, Allan RN, Faust SN. New approaches to the treatment of biofilm-related infections. J Infect. 2014;69:S47–52.CrossRefPubMed
144.
Williams I, Venables WA, Lloyd D, Paul F, Critchley I. The effects of adherence to silicone surfaces on antibiotic susceptibility in Staphylococcus aureus. Microbiology. 1997;143:2407–13.CrossRefPubMed
145.
Williams MM, Yakrus MA, Arduino MJ, Cooksey RC, Crane CB, Banerjee SN, et al. Structural analysis of biofilm formation by rapidly and slowly growing nontuberculous mycobacteria. Appl EnvironMicrobiol. 2009;75:2091–8.
146.
Wingender J, Strathmann M, Rode A, Leis A, Flemming HC. Isolation and biochemical characterization of extracellular polymeric substances from Pseudomonas aeruginosa. Methods Enzymol. 2001;336:302–14.CrossRefPubMed
147.
Xu KD, McFeters GA, Stewart PS. Biofilm resistance to antimicrobial agents. Microbiology. 2000;146:547–9.CrossRefPubMed
148.
Zaidi S, Misba L, Khan AU. Nano-therapeutics: a revolution in infection control in post antibiotic era. Nanomedicine. 2017;13(7):2281–301.CrossRefPubMed
149.
Zambrano MM, Kolter R. Mycobacterial biofilms: a greasy way to hold it together. Cell. 2005;123:762–4.CrossRefPubMed
150.
Zamora N, Esteban J, Kinnari TJ, Celdran A, Granizo JJ, Zafra C. In-vitro evaluation of the adhesion to polypropylene sutures of nonpigmented, rapidly growing mycobacteria. Clin Microbiol Infect. 2007;13:902–7.CrossRefPubMed
151.
Zhang TC, Bishop PL. Evaluation of substrate and pH effects in a nitrifying biofilm. Wat Environ Res. 1996;68:1107–15.CrossRef
152.
Zlosnik JE, Costa PS, Brant R, Mori PY, Hird TJ, Fraenkel MC, Wilcox PG, Davidson AGF, Speert DP. Mucoid and nonmucoid Burkholderia cepacia complex bacteria in cystic fibrosis infections. Am J Respir Crit Care Med. 2011;183:67–72.CrossRefPubMed
153.
Zuberi A, Ahmad N, Khan AU. CRISPRi induced suppression of fimbriae gene (fimH) of a Uropathogenic Escherichia coli: An approach to inhibit microbial biofilms. Front Immunol. 2017a;8:1552.CrossRefPubMedPubMedCentral
154.
Zuberi A, Misba L, Khan AU. CRISPR interference (CRISPRi) inhibition of luxS gene expression in E. coli: an approach to inhibit biofilm. Front Cell Infect Microbiol. 2017b;7:214.CrossRefPubMedPubMedCentral
Metadata
Title
Antibiotics versus biofilm: an emerging battleground in microbial communities
Authors
Divakar Sharma
Lama Misba
Asad U. Khan
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2019
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-019-0533-3

Other articles of this Issue 1/2019

Antimicrobial Resistance & Infection Control 1/2019 Go to the issue

Research

Prescribing practices using WHO prescribing indicators and factors associated with antibiotic prescribing in six community pharmacies in Asmara, Eritrea: a cross-sectional study

Research

Evaluation of co-transfer of plasmid-mediated fluoroquinolone resistance genes and blaNDM gene in Enterobacteriaceae causing neonatal septicaemia

Research

Patterns in the longitudinal oropharyngeal microbiome evolution related to ventilator-associated pneumonia

Research

The anti-virulence effect of cranberry active compound proanthocyanins (PACs) on expression of genes in the third-generation cephalosporin-resistant Escherichia coli CTX-M-15 associated with urinary tract infection

Research

Cross-border comparison of antimicrobial resistance (AMR) and AMR prevention measures: the healthcare workers’ perspective

Research

Study of genetic diversity, biofilm formation, and detection of Carbapenemase, MBL, ESBL, and tetracycline resistance genes in multidrug-resistant Acinetobacter baumannii isolated from burn wound infections in Iran
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits